I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 12 studies | 72% ± 28% | |
| type II pneumocyte | 4 studies | 36% ± 18% | |
| epithelial cell | 3 studies | 18% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 12 studies | 72% ± 28% | |
| type II pneumocyte | 4 studies | 36% ± 18% | |
| epithelial cell | 3 studies | 18% ± 2% |
Insufficient scRNA-seq data for expression of AGER at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 100% | 4476.35 | 653 / 653 | 99% | 68.99 | 598 / 605 |
| uterus | 100% | 959.48 | 170 / 170 | 96% | 10.14 | 440 / 459 |
| ovary | 100% | 947.24 | 180 / 180 | 92% | 11.51 | 397 / 430 |
| lung | 100% | 43644.39 | 578 / 578 | 90% | 75.97 | 1038 / 1155 |
| bladder | 100% | 822.24 | 21 / 21 | 88% | 15.81 | 441 / 504 |
| adrenal gland | 94% | 458.14 | 242 / 258 | 83% | 6.88 | 192 / 230 |
| kidney | 100% | 884.56 | 89 / 89 | 75% | 8.75 | 678 / 901 |
| prostate | 99% | 1236.17 | 243 / 245 | 75% | 5.30 | 375 / 502 |
| brain | 76% | 381.64 | 2019 / 2642 | 96% | 11.97 | 674 / 705 |
| esophagus | 97% | 674.39 | 1405 / 1445 | 73% | 6.08 | 133 / 183 |
| intestine | 100% | 869.22 | 963 / 966 | 67% | 4.07 | 352 / 527 |
| breast | 98% | 498.55 | 449 / 459 | 65% | 4.46 | 724 / 1118 |
| skin | 86% | 377.00 | 1562 / 1809 | 76% | 6.72 | 357 / 472 |
| stomach | 94% | 456.57 | 336 / 359 | 60% | 3.11 | 172 / 286 |
| pancreas | 57% | 205.04 | 188 / 328 | 90% | 8.03 | 161 / 178 |
| liver | 86% | 355.22 | 195 / 226 | 49% | 3.84 | 199 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 16.11 | 29 / 29 |
| spleen | 100% | 2355.48 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 65.24 | 1 / 1 |
| peripheral blood | 98% | 1275.00 | 908 / 929 | 0% | 0 | 0 / 0 |
| adipose | 97% | 480.76 | 1165 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 90% | 406.21 | 1207 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 78% | 6.89 | 35 / 45 |
| heart | 70% | 251.65 | 601 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 51% | 2.72 | 41 / 80 |
| muscle | 16% | 42.04 | 126 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0001914 | Biological process | regulation of T cell mediated cytotoxicity |
| GO_0032722 | Biological process | positive regulation of chemokine production |
| GO_0042104 | Biological process | positive regulation of activated T cell proliferation |
| GO_1901222 | Biological process | regulation of non-canonical NF-kappaB signal transduction |
| GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
| GO_0006954 | Biological process | inflammatory response |
| GO_1900271 | Biological process | regulation of long-term synaptic potentiation |
| GO_0001774 | Biological process | microglial cell activation |
| GO_0007611 | Biological process | learning or memory |
| GO_0150104 | Biological process | transport across blood-brain barrier |
| GO_0048143 | Biological process | astrocyte activation |
| GO_0046330 | Biological process | positive regulation of JNK cascade |
| GO_0031175 | Biological process | neuron projection development |
| GO_1902961 | Biological process | positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process |
| GO_0032735 | Biological process | positive regulation of interleukin-12 production |
| GO_1904645 | Biological process | response to amyloid-beta |
| GO_2000514 | Biological process | regulation of CD4-positive, alpha-beta T cell activation |
| GO_0007155 | Biological process | cell adhesion |
| GO_0001934 | Biological process | positive regulation of protein phosphorylation |
| GO_0050727 | Biological process | regulation of inflammatory response |
| GO_1900745 | Biological process | positive regulation of p38MAPK cascade |
| GO_0032693 | Biological process | negative regulation of interleukin-10 production |
| GO_2000439 | Biological process | positive regulation of monocyte extravasation |
| GO_1903523 | Biological process | negative regulation of blood circulation |
| GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
| GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
| GO_0048167 | Biological process | regulation of synaptic plasticity |
| GO_0001666 | Biological process | response to hypoxia |
| GO_1900453 | Biological process | negative regulation of long-term synaptic depression |
| GO_1900744 | Biological process | regulation of p38MAPK cascade |
| GO_2001200 | Biological process | positive regulation of dendritic cell differentiation |
| GO_0071639 | Biological process | positive regulation of monocyte chemotactic protein-1 production |
| GO_0150003 | Biological process | regulation of spontaneous synaptic transmission |
| GO_0034116 | Biological process | positive regulation of heterotypic cell-cell adhesion |
| GO_0045056 | Biological process | transcytosis |
| GO_1900272 | Biological process | negative regulation of long-term synaptic potentiation |
| GO_1904472 | Biological process | positive regulation of endothelin production |
| GO_0050930 | Biological process | induction of positive chemotaxis |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_1904646 | Biological process | cellular response to amyloid-beta |
| GO_0009611 | Biological process | response to wounding |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_0010255 | Biological process | glucose mediated signaling pathway |
| GO_0072657 | Biological process | protein localization to membrane |
| GO_0032755 | Biological process | positive regulation of interleukin-6 production |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0016324 | Cellular component | apical plasma membrane |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0098794 | Cellular component | postsynapse |
| GO_0001650 | Cellular component | fibrillar center |
| GO_0009986 | Cellular component | cell surface |
| GO_0030054 | Cellular component | cell junction |
| GO_0050785 | Molecular function | advanced glycation end-product receptor activity |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0060090 | Molecular function | molecular adaptor activity |
| GO_0044877 | Molecular function | protein-containing complex binding |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0001540 | Molecular function | amyloid-beta binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005044 | Molecular function | scavenger receptor activity |
| GO_0005055 | Molecular function | laminin receptor activity |
| GO_0044548 | Molecular function | S100 protein binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | AGER |
| Protein name | Advanced glycosylation end product-specific receptor RAGE3 (Advanced glycosylation end product-specific receptor variant sRAGE1) Advanced glycosylation end product-specific receptor variant AA (Receptor for advanced glycation end-products) Advanced glycosylation end product-specific receptor Advanced glycosylation end product-specific receptor (Advanced glycosylation end products transcript variant) (Soluble RAGE variant 5) Advanced glycosylation end product-specific receptor, splice variant 6 Advanced glycosylation end product-specific receptor (Receptor for advanced glycosylation end-products deletion exon3-10 variant) Advanced glycosylation end product-specific receptor, splice variant 9 RAGE isoform NtRAGE-delta Receptor for advanced glycosylation end-products deletion exon2-6 variant RAGE isoform sRAGE-delta Advanced glycosylation end product-specific receptor, splice variant 2 Advanced glycosylation end product-specific receptor, splice variant 7 Receptor for advanced glycation end-products Advanced glycosylation end product-specific receptor (Receptor for advanced glycosylation end products) Advanced glycosylation end product-specific receptor, splice variant 4 RAGE isoform delta Advanced glycosylation end product-specific receptor variant sRAGE2 Advanced glycosylation end product-specific receptor, splice variant 8 Advanced glycosylation end product-specific receptor variant BB Advanced glycosylation end product-specific receptor, splice variant 5 |
| Synonyms | RAGE |
| Description | FUNCTION: Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans . Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes . These ligands accumulate at inflammatory sites during the pathogenesis of various diseases, including diabetes, vascular complications, neurodegenerative disorders, and cancers and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction or inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B . Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators . Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons . ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Participates in endothelial albumin transcytosis together with HMGB1 through the RAGE/SRC/Caveolin-1 pathway, leading to endothelial hyperpermeability . Mediates the loading of HMGB1 in extracellular vesicles (EVs) that shuttle HMGB1 to hepatocytes by transferrin-mediated endocytosis and subsequently promote hepatocyte pyroptosis by activating the NLRP3 inflammasome . Promotes also extracellular hypomethylated DNA (CpG DNA) uptake by cells via the endosomal route to activate inflammatory responses . . |
| Accessions | ENST00000383279.8 [Q15109-2] ENST00000375056.6 E9LVY7 ENST00000550196.5 ENST00000546535.2 ENST00000444630.5 Q71BG7 ENST00000438221.6 [Q15109-4] Q3L1R3 ENST00000441804.6 [Q15109-2] ENST00000375055.6 [Q15109-3] ENST00000549758.5 [Q15109-6] ENST00000451115.6 [Q15109-1] F1ABN1 ENST00000375067.7 [Q15109-2] ENST00000453588.5 [Q15109-3] C0IP16 ENST00000547651.2 [Q15109-4] ENST00000549626.3 A0A0G2JL65 E9LVY6 ENST00000436653.5 ENST00000375076.9 [Q15109-1] ENST00000454284.5 ENST00000412470.6 [Q15109-2] ENST00000549227.5 A0A0G2JL23 ENST00000538695.2 ENST00000553014.5 F1ABN2 Q101R3 ENST00000448768.6 ENST00000416532.5 C0IP14 ENST00000426138.6 A0A0G2JL21 ENST00000547770.5 ENST00000427822.6 ENST00000551254.5 [Q15109-4] ENST00000549776.3 F1ABN0 F1ABN5 ENST00000550959.5 ENST00000548935.4 ENST00000424145.6 ENST00000552517.5 ENST00000547328.5 [Q15109-6] A0A0G2JKB6 ENST00000375069.7 [Q15109-6] ENST00000551378.4 ENST00000552621.4 ENST00000447921.6 [Q15109-1] ENST00000550441.5 ENST00000375070.7 ENST00000549839.5 ENST00000549168.4 F1ABM9 A0A0G2JJW2 ENST00000450110.5 ENST00000455471.5 Q15109 F1ABN4 Q3L1R2 B5A982 ENST00000548009.4 ENST00000550854.5 ENST00000383275.6 [Q15109-3] ENST00000434502.5 Q101R5 ENST00000436456.6 [Q15109-1] ENST00000550885.5 ENST00000552209.5 ENST00000456918.6 [Q15109-1] A8MS87 ENST00000552891.5 Q5SSZ3 Q101R2 ENST00000547155.5 ENST00000548464.3 [Q15109-6] ENST00000418313.5 ENST00000552991.5 ENST00000551684.5 ENST00000547213.5 ENST00000441180.6 [Q15109-2] ENST00000449037.5 [Q15109-3] A0A0G2JID9 Q71BB6 ENST00000548959.5 ENST00000550562.5 [Q15109-4] ENST00000426320.5 ENST00000412794.5 ENST00000424476.5 ENST00000551244.4 ENST00000551381.5 [Q15109-6] ENST00000453119.5 ENST00000551677.3 ENST00000452945.5 ENST00000548034.3 ENST00000415973.5 ENST00000551827.4 [Q15109-4] A0A0G2JJF5 A0A0G2JL37 F1ABN3 ENST00000432831.5 [Q15109-3] E9LVY5 Q5SSZ2 ENST00000441753.5 |
